Drug intelligence / Profile preview

ETI-001

Development stage: Preclinical
Lead developer: Elastrin Therapeutics
Administration: Oral

Overview

**ETI-001** is a preclinical drug candidate developed by Elastrin Therapeutics for cardiovascular diseases. Limited public information is available on its specific mechanism of action, indications beyond the broad therapeutic area, or clinical details, indicating it remains in early-stage research with no disclosed trial data or regulatory progress as of the latest records.[3]

Beyond the preview

Go deeper on ETI-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ETI-001.

Explore the full profile